Detalles de la búsqueda
1.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med
; 386(4): 316-326, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35081280
2.
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
Ann Rheum Dis
; 81(11): 1491-1503, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35922124
3.
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Ann Rheum Dis
; 80(1): 134-136, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33046447
4.
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
Rheumatol Ther
; 10(2): 357-373, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36526796
5.
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.
Rheumatol Ther
; 9(2): 411-433, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921355
6.
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.
ACR Open Rheumatol
; 3(3): 173-184, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33570260
Resultados
1 -
6
de 6
1
Próxima >
>>